FDA grants fast track status to Vir Biotechnology's prostate cancer drug

October 8, 2026 8:30 AM

Vir Biotechnology, Inc. (Nasdaq: VIR) announced that the U.S. Food and Drug Administration granted Fast Track designation to VIR-5500, a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found